Hydrocodone extended-release - Teva Pharmaceutical Industries

Drug Profile

Hydrocodone extended-release - Teva Pharmaceutical Industries

Alternative Names: CEP-33237; Hydrocodone bitartrate extended-release - Teva; Tamper-deterrent hydrocodone; Twice-daily hydrocodone - Teva; VANTRELAER

Latest Information Update: 21 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Teva Pharmaceutical Industries
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Pain

Most Recent Events

  • 18 Jan 2017 Registered for Pain in USA (PO) - First global approval
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in Canada (PO, Controlled release)
  • 07 Jun 2016 The Anaesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee recommends approval of hydrocodone extended release for Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top